METHODS FOR TREATMENT OF DISEASES
The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
1 . A unit dose formulation comprising at least 50 mg of a superoxide dismutase mimetic in a container, the superoxide dismutase mimetic corresponding to Formula (GC4419):
wherein X and Y are independently neutral or negatively-charged ligands.
2 . The unit dose formulation of claim 1 , which comprises at least 600 mg of the superoxide dismutase mimetic.
3 . The unit dose formulation of claim 1 , wherein the superoxide dismutase mimetic is in the form of a lyophilized powder.
4 . The unit dose formulation of claim 1 , wherein the container further includes a pharmaceutically acceptable carrier.
5 . The unit dose formulation of claim 4 , wherein the pharmaceutically acceptable carrier comprises a buffered saline solution.
6 . The unit dose formulation of claim 4 , wherein the pharmaceutically acceptable carrier comprises a bicarbonate-buffered saline solution.
7 . The unit dose formulation of claim 1 , wherein X and Y are independently selected from monodentate ligands.
8 . The unit dose formulation of claim 1 , wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.
9 . The unit dose formulation of claim 8 , wherein X and Y are chloro ligands.
10 . The unit dose formulation of claim 1 , wherein the formulation is stored in a container for storage or for administration to a patient.
11 . The unit dose formulation of claim 10 , wherein the container is a vial, a syringe, or an IV bag or bottle.
12 . A method of treating a disease or condition in a human patient, the method comprising administering to the patient at least 25 mg of a superoxide dismutase mimetic at a rate of at least 100 mg/hr, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
and X and Y are independently neutral or negatively-charged ligands.
13 . The method of claim 12 , wherein the superoxide dismutase mimetic is administered at a rate of at least 600 mg/hr.
14 . The method of claim 12 , wherein at least 50 mg of the superoxide dismutase mimetic is administered to the patient.
15 . The method of claim 12 , wherein at least 600 mg of the superoxide dismutase mimetic is administered to the patient.
16 . The method of claim 12 , wherein the administration occurs within a 15 minute time period.
17 . The method of claim 12 , wherein the administration occurs within a 60 minute time period.
18 . The method of claim 12 , wherein the superoxide dismutase mimetic is administered parenterally.
19 . The method of claim 12 , wherein the superoxide dismutase mimetic is administered intravenously.
20 . The method of claim 12 , wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.
21 .- 41 . (canceled)